Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. - Wikidata - awgldk - TriplyDB

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

http://www.wikidata.org/entity/Q43873037

about

Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation Transglutaminases: nature's biological glues Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Multiple Aspects of Gene Dysregulation in Huntington's Disease Physio-pathological roles of transglutaminase-catalyzed reactions Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death No quiet surrender: molecular guardians in multiple sclerosis brain Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases Cellular functions of tissue transglutaminase Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease The Role of Interleukin-22 and Its Receptor in the Development and Pathogenesis of Experimental Autoimmune Uveitis Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms A novel hemostatic sealant composed of gelatin, transglutaminase and thrombin effectively controls liver trauma-induced bleeding in dogs.ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.Short time-series microarray analysis: methods and challenges.Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins.Therapeutic Strategies in Huntington's Disease Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics.Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast Cystamine preparations exhibit anticoagulant activity Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

P2860

Q21144448-64EC09B5-AF0F-4E07-8FF0-9303A5E0D072 Q24308854-B8573280-E55B-4856-82C1-16D67D3D33FC Q24324878-2B1C53C2-103A-4FA5-B3BE-E9E17B0F6657 Q24534936-8D11872A-7EEF-430A-9A01-813A4B1018C4 Q24548047-37BB0BD2-E339-4121-B335-6CDC445B318B Q24605880-35058DA9-8122-4C70-86B0-B4EAD6FF756B Q24605961-20439FA7-9DFB-4FF7-A68D-8AD2C28C1EF3 Q24618141-6C9C334B-4A42-48FF-8B02-39E5F26B90D4 Q27005950-62A14368-D255-4BEA-92FA-7813731B973C Q28069852-6535284B-E8BF-499D-B91D-62CADB9FE85D Q28084633-3D2B3233-DFFA-43C6-BEC0-CC0B3757C391 Q28248796-FE36F9E3-B245-44C9-9261-766DDB71ED91 Q28260600-C9D6B444-4FB4-4194-8208-16548DCF8CD0 Q28505492-B77D79C8-58FB-43B6-9F52-B13B5177C993 Q28551977-68C5A0C6-234F-465F-8536-2960FD07173A Q28592026-3A937C0B-B146-4FA8-A4FB-BA1146FF3AD7 Q30430562-3B3529CC-08DE-4359-B1FE-AC9DB72595A2 Q30478632-FC439962-4691-4E75-85A2-CE836A2F8398 Q30844932-B09C3166-7D49-40E4-A416-6537C61E7AA8 Q31122113-05D44B9A-97BB-4566-8B5D-5759A877671D Q33370734-7D6CDBE4-E2D4-4B24-ABCD-6F8FF92B5DE2 Q33635140-9C4ABBFB-34D7-4CAA-9D9D-6B6DF0216627 Q33737470-5A0C6E68-F653-425D-AAC8-C66F56FBCE81 Q33747446-2DB174E8-284E-4E53-8C4C-4EAFD155E712 Q33790829-9AB1E954-591C-4D26-B015-29023D8B676D Q33793353-DC334EB9-CF48-47D0-BE2F-FF895C6ACEAC Q33812932-25DBE140-66AE-449F-BD26-EC292624DE80 Q33912442-FD654EF6-34CD-45C9-B86D-A56D2467D380 Q33928419-F0FA145E-5130-4AD4-BC3D-32AA580D79B7 Q33930636-5E7677D4-38E6-41D4-AC3B-AE995018775B Q33936969-3647F20A-1C68-48E6-9406-24C8A0EA144A Q34077018-8837A138-2402-44F0-8704-D5DC6ABED659 Q34154776-E5E007E8-0F09-4FF1-9FBE-4AEF56D26EC8 Q34281322-9C432281-976B-48D0-BA33-82394C68639C Q34323333-BE8F895D-3DDE-4B72-AC39-084DFD29CF9E Q34365610-0BC442EF-3C52-4CF5-99EE-BB33B72CAE2F Q34473794-443EA3D6-DF01-4780-9957-BA75B5232A2A Q34743269-B0AF3B05-F173-4F6E-B2E3-DA1C15F5AB05 Q34763178-FE095D77-0B5B-44C6-890B-EB0268B6D616 Q34763209-7CAE173E-4328-494C-9CCA-78984197AD86

P2860

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

http://www.wikidata.org/entity/Q43873037

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@en

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@nl

type

label

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@en

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@nl

prefLabel

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@en

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@nl

P1433

Q43873037-3207B317-1DAE-4A7F-AD89-B6A3E1692EFD

P1476

Q43873037-893B35E7-5A2A-4DA0-9587-D021390E79C8

P2093

Q43873037-0786590A-8322-4991-8E17-5BC4ED919F24

Q43873037-4CDBAEBE-4BF8-43FD-943C-932D8AC08EFC

Q43873037-5BDBAD3B-17BB-4535-85AB-489DC6B1933F

Q43873037-8FBCAD6F-0E4C-470B-8E79-E42B4CB9E319

Q43873037-A3218959-B1FE-4FFE-8C72-B7F1C3FDE8D4

Q43873037-B200DA12-CCEE-4260-AAE9-A109926E2EB9

Q43873037-BFE2F039-0953-498A-8BEC-BCEDC4966FDE

Q43873037-E479E899-DD50-4FC7-995A-C2CCFCD8ACC4

P2888

Q43873037-7331DE75-54B7-484E-9F6E-C4496C3A8833

P304

Q43873037-CBD53BA4-9967-4EFB-B818-B82376796143

P31

Q43873037-69B0C6A5-5359-4EA1-9F07-3B5F8EDC6F5D

P356

Q43873037-A7F27A0B-7D99-4FD2-AF01-54732205523E

P407

Q43873037-1F3BBA83-1B67-4130-948D-30CFB3147901

P433

Q43873037-8E031C7E-7CBD-46CA-87FC-80CF178394A7

P478

Q43873037-59AC1449-A3EA-44FF-825B-FCA6E24E3DD2

P577

Q43873037-83E37F73-092B-4662-8BFE-B22433E8B31F

P5875

Q43873037-9D6EEBD7-46C6-49FB-BFB5-2E6243A1591F

P6179

Q43873037-B47F3525-40C2-413F-A2EA-3B554B8FD643

P698

Q43873037-884961C4-373A-4DA3-AA6F-C88EFC606928

P921

Q43873037-6A2F88E3-6F78-405C-9BC9-D9C757DABAA9

P356

P1433

Nature Medicine

P1476

Prolonged survival and decreas ...... utaminase inhibitor cystamine.

@en

P2093

Dennis Mitchell

http://www.w3.org/2001/XMLSchema#string

Dorothee Chabas

http://www.w3.org/2001/XMLSchema#string

Joe E Springer

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

Marcela V Karpuj

http://www.w3.org/2001/XMLSchema#string

Mark W Becher

http://www.w3.org/2001/XMLSchema#string

Rosetta Pedotti

http://www.w3.org/2001/XMLSchema#string

Sawsan Youssef

http://www.w3.org/2001/XMLSchema#string

P2888

P304

143-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM0202-143

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11538044

http://www.w3.org/2001/XMLSchema#string

P6179

1043117163

http://www.w3.org/2001/XMLSchema#string

P698

11821898

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease